相关产品推荐更多 >

CD140b pY857 Antibody, anti-mouse, APC, REAfinity™, 30 µg in 1 mL
询价
CD203c Antibody, anti-human, PE-Vio® 770, 30 tests in 300 µL
询价
CD88 (C5AR) Antibody, anti-human, APC, 100 tests in 1 mL
询价
c-Cbl pY774 Antibody, anti-human, PE, REAfinity™, 100 tests in 1 mL
询价
CD34 Antibody, anti-human, FITC, 100 tests in 200 µL
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原:
CD44
- 亚型:
recombinant human IgG1
- 形态:
Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
- 保存条件:
避光,4-8℃
- 克隆性:
REA690
- 标记物:
Vio Bright B515
- 适应物种:
human, non-human primate
- 保质期:
24个月
- 供应商:
Miltenyi Biotec
- 宿主:
human cell line
- 应用范围:
Flow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry, Mass cytometry
- 浓度:
1:50
- 抗体英文名:
CD44 Antibody, anti-human, REAfinity™
- 抗体名:
CD44 Antibody, anti-human, REAfinity™
- 规格:
30 tests in 60 µL
Identification and enumeration of CD44+ cells by flow cytometryClone REA690 recognizes the CD44 antigen. CD44 is a marker for many types of cancer stem cells (CSCs), including breast CSCs that possess higher tumorigenicity and metastatic potential, colorectal, pancreatic, and prostate CSCs. In addition, expression was observed in several cancers as well as on carcinoma cell lines. Here, CD44 plays a role in cancer cell migration and matrix adhesion in response to a cellular microenvironment, thus enhancing cellular aggregation and tumor cell growth. CD44 is also expressed on mesodermal cells, such as hematopoietic, fibroblastic, and glial cells. | Additional information: Clone REA690 displays negligible binding to Fc receptors.
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
Al-Hajj, M. et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100: 3983–3988. | Dalerba, P. et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U.S.A. 104: 10158–10163. | Collins, A. T. et al. (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65: 10946–10951. | Aruffo, A. et al. (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303–1313. | Patrawala, L. et al. (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25: 1696–1708. | Wang, L. et al. (2013) Enrichment of prostate cancer stem-like cells from human prostate cancer cell lines by culture in serum-free medium and chemoradiotherapy. Int. J. Biol. Sci. 9 (5): 472–479.
技术资料暂无技术资料 索取技术资料
文献支持
CD44 Antibody, anti-human, Vio® Bright B515, REAfinity™, 30 tests in 60 µL
询价





